Taysha Gene Therapies

About Taysha Gene Therapies

Taysha Gene Therapies is dedicated to developing gene therapies to transform the lives of patients with central nervous system (CNS) diseases caused by monogenic mutations. With a focus on targeted execution, they aim to dramatically improve patient outcomes and are committed to being an ally to the rare disease community.

Products & Services

TSHA-102:A gene therapy candidate for Rett syndrome, designed to address one of the most common genetic causes of severe intellectual disability in females.

Other Programs:Additional therapeutic candidates in the pipeline for CNS diseases.

Specialties

Gene Therapy Central Nervous System (CNS) Diseases Rett Syndrome Monogenic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: approximately $200.0 million FAN: 200000000	D: 2025-05-28 FD: 2025-05-28	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2024-06-26 FD: 2024-06-26	3 investors
3	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: up to $75 million FAN: 75000000	D: 2024-06-25 FD: 2024-06-25	3 investors
4	RT: Debt T: - FT: Debt	A: 40000000 MR: - FA: $40 million FAN: 40000000	D: 2023-12-19 FD: 2023-12-19	1 investors
5	RT: Private Placement T: - FT: Private Placement	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2023-08-21 FD: 2023-08-21	1 investors
6	RT: Private Placement T: - FT: Private Placement	A: 150000000 MR: - FA: 150 million FAN: 150000000	D: 2023-08-14 FD: 2023-08-14	11 investors

Public Offering Latest

2025-05-28

$200.0M

4 investors (Pro only)

Public Offering 2024-06-26

$75.0M

Public Offering 2024-06-25

$75.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sean Nolan

Chief Executive Officer and Board Chairman

S

Sukumar Nagendran

President and Head of Research and Development

K

Kamran Alam

Chief Financial Officer

E

Emily McGinnis

Chief Patient and External Affairs Officer

R

Rumana Haque-Ahmed

Chief Regulatory Officer

F

Fred Porter

Chief of Staff and Technical Operations Officer

View 29 more team members with Pro

Unlock Full Team Directory

Recent News